Andromeda Biotech Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Andromeda Biotech Ltd.
The Irish biotech has launched a Phase IIb/III trial of its sphingosine 1 phosphate receptor modulator mocravimod, expanding a mode of action that has been successful in autoimmune indications into the hematology space.
Taiho will pay Cullinan Oncology up to $405m for their joint venture and lead candidate for a form of lung cancer. Plus deals involving Zhaoke/Visus, AnGes/Eiger, Juniper/Helsinn, Peak Bio and more.
At a time when the sector has fallen out of favor with venture capitalists and public markets, Irish biotech Priothera is accessing funds from the EU to advance a Phase IIb/III study of mocravimod for acute myeloid leukemia patients receiving hematopoietic stem cell transplants.
VC Playbook: The fundamentals do not change in life sciences investing – good science, unmet need and social responsibility.
- Large Molecule
- Other Names / Subsidiaries
- Clal Biotechnology Industries Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.